THE NEED FOR REPRESENTATIVE EXAMPLES In Juno Therapeutics v. Kite Pharma, the U.S. Court of Appeals for the Federal Circuit invalidated a CAR-T cell therapy patent due to an insufficient written description. The patent broadly claimed a genus of chimeric antigen receptors, but the court found that the application failed to provide enough representative species or structural details to justify such broad claims. This decision reaffirmed that for biotechnology inventions, a few examples may not be enough — applicants must disclose a range of embodiments to support a broad claim.
GUIDING CASE LAW
JUNO THERAPEUTICS V. KITE PHARMA (2021)
Made with FlippingBook Annual report maker